Exclusive varieties of traditional Chinese medicine are popular at the opening of "supplementary feast" of Guangdong Basic Medicine

On Thursday, Guangdong released a list of essential drug supplements 278 varieties have been added to the supplementary catalogue in this round, including 131 new varieties of traditional Chinese medicine and more than 100 exclusive varieties For the quantity of this supplement, insiders from Guangdong Provincial Department of Health told Shanghai Securities News, "the original list of base drugs is not enough." The catalogue has greatly increased traditional Chinese medicine injection The reporter of Shanghai Securities News learned that Xuebijing injection of HongRi pharmaceutical and Tanreqing injection of Shanghai Kaibao have been selected, and these products are the core varieties that contribute the most to the company's performance In terms of Xuebijing injection of HongRi pharmaceutical, it is the only drug listed in China to treat sepsis and multiple organ dysfunction syndrome At present, Xuebijing is in short supply, according to a person from the company who told the Shanghai Securities News The company has started to carry out relevant preparations for the product to enter the national medical insurance catalog Tanreqing injection, the main product of Shanghai Kaibao, is a kind of traditional Chinese medicine injection for respiratory diseases At present, the company is carrying out the research and development of a series of products: according to the feedback requirements of the project approval department, the company has basically completed the research on 5ml injection, and is preparing to re declare; the capsule has applied for the new drug certificate and production approval document, and is waiting for the approval of SFDA; the oral liquid is in the third phase of clinical research "In the long run, antibiotic restriction policy will not be relaxed, and Tanreqing will be one of the direct beneficiaries This is also one of the important reasons why Shanghai Kaibao Tanreqing was selected into the new version of basic drugs " People familiar with the situation told the Shanghai Securities News that the current capacity bottleneck is still the most critical factor restricting the development of the company, which is expected to break through in the second half of the year In addition, it is worth noting that Baimai ointment of Qizheng Tibetan medicine has recently entered the supplement catalogue of Guangdong and Qinghai provinces According to the reporter's investigation, the profit of exclusive varieties of traditional Chinese medicine has always been high, which makes enterprises gain greater marketing and promotion advantages From a period of time in the future, the market is the world of exclusive varieties At the same time, the South China market represented by Guangdong accounts for 30% of the total market share of China's pharmaceutical industry Therefore, it has a positive impact on the annual performance growth of relevant pharmaceutical enterprises to enter the supplementary catalogue of Guangdong Province In the supplementary catalogue of Guangdong, some exclusive new varieties of listed companies of traditional Chinese medicine have also emerged For example, Tianshu tablet of Kangyuan pharmaceutical, Dazhu Hongjingtian price capsule and Tongsaimai Tablet, and Jinlida granule of Yiling pharmaceutical are all included in the supplementary catalogue of basic drugs in Guangdong Although the current quantity of these new varieties is not large, their potential to become large varieties in the future is increasing The reporter learned that one of the backgrounds that the varieties of traditional Chinese medicine are favored by the policy is that traditional Chinese medicine is becoming the national strategy of our country At the end of last month, authorities disclosed that the draft law on traditional Chinese medicine will be submitted to the State Council, and traditional Chinese medicine is expected to become a national strategy Industry insiders said that traditional Chinese medicine has a strategic advantage in the global economic competition, and is a unique feature and advantage field in China's pharmaceutical industry.